title: Effects of fluoxetine administration on mood response to tryptophan depletion in healthy subjects.
abstract: Short-term reduction in plasma tryptophan (tryptophan depletion) produces a relapse of depressive symptoms in 60% of previously depressed patients recently recovered with serotonin reuptake inhibitor treatment. Tryptophan depletion does not consistently increase depressive symptoms in unmedicated depressed patients or in depressed patients whose symptoms are remitted with a norepinephrine reuptake inhibitor. These data suggest that serotonin reuptake inhibitor treatment itself may confer vulnerability to the development of depressive symptoms during tryptophan depletion. In order to further investigate this possibility, six healthy individuals underwent double-blind placebo-controlled tryptophan depletion before and following six weeks of treatment with fluoxetine 20 mg/day. No increased vulnerability to the mood-lowering effects of tryptophan depletion occurred as a result of fluoxetine treatment. Additionally, fluoxetine treatment itself was not associated with changes in mood or quality of life in these healthy volunteers. These data indicate that serotonin reuptake inhibitor treatment alone does not produce the depressive effects of tryptophan depletion that are observed in serotonin reuptake inhibitor-treated depressed and obsessive compulsive disorder patients.
authors.affiliation: Clinical Neuroscience Research Unit, Abraham Ribicoff Research Facilities, Connecticut Mental Health Center, Department of Psychiatry, Yale University School of Medicine, New Haven, USA.
authors.forename: L C
authors.initials: LC
authors.lastname: Barr
authors.forename: G R
authors.initials: GR
authors.lastname: Heninger
authors.forename: W
authors.initials: W
authors.lastname: Goodman
authors.forename: D S
authors.initials: DS
authors.lastname: Charney
authors.forename: L H
authors.initials: LH
authors.lastname: Price
mesh_terms: D000328:Adult; D000339:Affect / Q000187:drug effects* / Q000502:physiology; D018687:Antidepressive Agents, Second-Generation / Q000494:pharmacology*; D003866:Depressive Disorder / Q000503:physiopathology; D004311:Double-Blind Method; D005260:Female; D005473:Fluoxetine / Q000494:pharmacology*; D006801:Humans; D008297:Male; D011788:Quality of Life; D012307:Risk Factors; D014364:Tryptophan / Q000097:blood*
chemical_list: D018687:Antidepressive Agents, Second-Generation; D005473:Fluoxetine; D014364:Tryptophan